Corrigendum to 'Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry' [Eur J Cancer 180 (2023) 71-84].

The authors regret that the acknowledgements section in the published article did not include the acknowledgement for the administrative project management provided by Martina Nesper-Brock. The full and correct acknowledgements are given here: The authors thank patients, families and submitting centers for participation in this study. The authors thank Sabine Brokmeier, Jasmin Nowy, Linda Keilbach and Christina Vasanthakumar for technical and logistic assistance, as well as Martina Nesper-Brock for administrative project management. The graphical abstract was created with BioRender.com. The authors would like to apologise for any inconvenience caused. Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registryEuropean Journal of CancerVol. 180PreviewPrecision oncology requires diagnostic accuracy and robust detection of actionable alterations. The Pediatric Targeted Therapy (PTT) 2.0 program aims at improving diagnostic accuracy by addition of molecular analyses to the existing histological diagnosis and detection of actionable alterations for relapsed paediatric oncology patients, in cases with limited availability of tumour material. Full-Text PDF